Parkinson’s disease (PD), a progressive disease of the central nervous system, initially relies on medications to control the symptoms of the disease. If a patient with primary PD is diagnosed with more than 5 years of disease and the effectiveness of medications has significantly decreased, surgery may be considered. Deep brain electrical stimulation (DBS, commonly known as a pacemaker) therapy is the preferred option, although it is less effective when the disease progresses to an advanced stage. DBS is performed through electrodes implanted in the brain, which deliver electrical impulses to the nuclei involved in motor control to modulate abnormal electrical activity and reduce and control symptoms. The implantation of electrodes is minimally invasive and does not require craniotomy, the patient remains awake, and any discomfort can be adjusted in time. This technique was pioneered by French scholar Benabid in 1987, and has been gradually matured and perfected. Nearly 90,000 PD patients have been treated worldwide, and our hospital has also carried out DBS surgery for Parkinson’s disease. To date, more than 4,300 cases have been completed by our national counterparts, and their safety and efficacy have been clinically proven. The recently released “Expert Consensus on Deep Brain Electrical Stimulation Therapy for Parkinson’s Disease in China” believes that surgery can be considered when primary PD patients taking levodopa-based drugs, which had good efficacy, have significantly decreased in efficacy or have severe motor fluctuations or isokinetic disorders that affect the quality of life. Patients usually have a disease duration of more than 5 years and are in principle no older than 75 years old, but this can be moderately relaxed depending on the assessment results and the patient’s wishes. However, the technique is expensive and difficult for some patients to afford. The good thing is that the relevant parties have started to explore the relevant system, hoping to save more PD patients. For example, Qingdao recently took the lead in including the special material assistance program for DBS for Parkinson’s disease into the urban major medical assistance program, which greatly reduces the financial burden of patients by introducing a co-payment mechanism, allowing more patients to enjoy the advanced technology. While seeing the light of day, patients also need to be reminded that surgery can mainly improve the quality of life significantly and control the main symptoms of the disease, but does not cure Parkinson’s disease, which can still progress, although most patients are able to reduce their medication after surgery. In addition, there is a time window for choosing the timing of surgery. According to the Hoehn-Yahr staging commonly used in PD (a total of 5 stages), patients in stages 2.5 to 4 are suitable. In stage 5 patients, who are confined to a wheelchair or bedridden and completely unable to take care of themselves, surgery is not very valuable. The biggest risk of this surgery is intracranial hemorrhage, which is not high <1%.